PMC5632488_01
Sequence of events for initiation of molecular targeted therapy and for appearance of metastatic lesions.
CRIONM2017-2648471.001.jpg
PMC5632488_01_CRIONM2017-2648471.001.jpg
fig1
We subsequently increased the sorafenib dose to 800 mg/day (Figure 1).
PET-CT showing (a) lymph node metastasis near the bifurcation of trachea and lumbar vertebral metastasis before sorafenib rechallenge therapy and (b) that the metastatic lesion vanished 5 months after the rechallenge therapy.
CRIONM2017-2648471.002.jpg
PMC5632488_01_CRIONM2017-2648471.002.jpg
fig2
However, PET-CT revealed new lymph node metastasis near the tracheal bifurcation (Figure 2(a)). In the next month (5 months after the sorafenib rechallenge), PET-CT showed dramatic shrinkage of the metastatic lesions, considered a complete response (Figure 2(b)).